Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 4691502

Next Previous
Drug Profile

PF 4691502

Alternative Names: PF-04691502; PF-4691502

Latest Information Update: 22 Jul 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Pyridones; Pyrimidines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Endometrial cancer; Solid tumours

Most Recent Events

  • 22 Jul 2020 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 111th Annual Meeting of the American Association for Cancer Research - II(AACR-2020)
  • 23 Jan 2014 Pfizer terminates a phase II trial in Endometrial cancer in USA, Australia, Canada, Germany, Japan, Poland, Russia, Slovakia, Spain and the United Kingdom (NCT01420081)
  • 12 Nov 2012 Discontinued - Phase-II for Endometrial cancer in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top